





Title: The impact of maternal pre-pregnancy impaired fasting glucose on preterm birth and 
large for gestational age: a large population-based cohort study 
Authors: 
James Jie Tang, PhD
 1,2,3,#
; Xinhong Zhu, MD
 4
; Mingzhen Li, MD 
5,6
; Dongming Huang, 
MD 
5,6
; Qingguo Zhao, PhD 
5,6,7,# 
Authors’ affiliations 
1. Department of Preventive Medicine, School of Public Health, Guangzhou Medical 
University, Xinzao, Panyu District, 511436, Guangzhou, P.R. China. 
2. The First Affiliated Hospital of Guangzhou Medical University, 151
st
, Yanjiang Road 
West, Haizhu District, 510220 Guangzhou, P.R. China. 
3. Faculty of Education, Health and Wellbeing, University of Wolverhampton, Millennium 
City Building, Wulfruna Street, Wolverhampton, WV1 1LY, UK. 
4. Guangdong Women and Children Hospital, 521-523 Xingnan Street, Panyu District, 
511442 Guangzhou, P.R. China. 
5. Guangdong Institute of Family Planning Science and Technology, 17
th
 Meidong Road, 
Yuexiu District, 510245 Guangzhou, P.R. China. 
6. Family Planning Special Hospital of Guangdong, 17
th
 Meidong Road, Yuexiu District, 
510245 Guangzhou, P.R. China. 
7. National Health Committee of China (NHCC) Key Laboratory of Male Reproduction and 
Genetics, 17
th
 Meidong Road, Yuexiu District, 510245 Guangzhou, P.R. China. 
#, Corresponding author: Dr. James Jie Tang (Faculty of Education, Health and Wellbeing, 
University of Wolverhampton, Millennium City Building, Wulfruna Street, Wolverhampton, 
WV1 1LY, UK, Email: James.Tang@wlv.ac.uk; Tel:+44 019023202950) & Professor 
Qingguo Zhao (Family Planning Special Hospital of Guangdong, 17
th
 Meidong Road, Yuexiu 
District, 510245 Guangzhou, P.R. China; Email: zqgfrost@gdszjk.org.cn; Tel:+86 
02081375023)  
Declaration of interests: The authors report no conflict of interest. 
Funding: This work was supported by grants National Natural Science Foundation of 
China (81773457 & 81302445 to JJT). The funder had no role in study design, data 






Word count: Abstract: 465; main text: 4295; Tables: 6 (3 for main text, 3 for appendix); 
Figures: 5 (1 for main text, 4 for appendix) 
 
Condensation: Maternal pre-pregnancy impaired fasting glucose increases the risk of 
preterm birth and larger for gestational age 
 
Short title: Impact of pre-pregnancy impaired fasting glucose on preterm birth and large 
for gestational age 
AJOG at a Glance  
A. Little is known about the impact of maternal pre-pregnancy impaired fasting glucose 
(IFG) on preterm birth (PTB) and large for gestational age (LGA). 
B. In this large cohort study, we found that compared with women with 
normoglycaemia, women with pre-pregnancy IFG had 7.0%, 10.0% and 17.0% higher 
risk of PTB, LGA and severe LGA, these associations were similar in subgroups of 
women with various baseline characteristics. Fasting glucose below the WHO cut-
point for IFG also increased the risk of LGA and severe LGA. 
C. Our data, for the first time, indicated that maternal pre-pregnancy IFG increases the 
risk of PTB, LGA and severe LGA. WHO cut-point of IFG is too restrictive and 











Background  The impact of maternal pre-pregnancy impaired fasting glucose on preterm 
birth and large for gestational age has been poorly understood.  
Objectives  We aimed to estimate the impact of pre-pregnancy impaired fasting glucose 
defined by the WHO cut-point on the risk of preterm birth and large for gestational age, and 
to investigate whether the WHO cut-point of impaired fasting glucose was appropriate for 
identifying women at the risk of preterm birth and large for gestational age among the 
Chinese population. 
Study Design  This was a retrospective cohort study of women from the National Free 
Preconception Health Examination Project with singleton birth from 121 counties/districts in 
21 cities of Guangdong Province, China, from 1
st
 January 2013 to 31
st
 December 2017. 
Women were included if pre-pregnancy fasting glucose was less than 7.0mmol/L. The 
primary outcomes were preterm birth (gestational age <37 weeks), early preterm birth 
(gestational age <34 weeks), large for gestational age (birth weight by gestational age >90
th
 
percentile based on the international standards in the INTERGROWTH-21
st
) and severe large 
for gestational age (birth weight by gestational age >97
th
 percentile). We calculated the 
adjusted risk ratio for impaired fasting glucose, and a 1 standard deviation increase in fasting 
glucose.  
Results  We included 640469 women. Of these, 31006 (4.84%) met the WHO cut-point for 
impaired fasting glucose, 32640 (5.10%) had preterm birth and 7201 (1.12%) had early 
preterm birth, 45532 (7.11%) had large for gestational age birth and 16231 (2.53%) had 
severe large for gestational age birth. Compared with women with normoglycaemia, women 
with pre-pregnancy impaired fasting glucose had a 7.0% higher risk of preterm birth 






(1.10, 1.06-1.14) and 17.0% higher risk of severe large for gestational age (1.17, 1.10-1.26). 
No significant association of pre-pregnancy impaired fasting glucose with early preterm birth 
was found. The association of pre-pregnancy impaired fasting glucose with preterm birth and 
large for gestational age were similar in subgroups of women with various baseline 
characteristics. Adjusted risk ratio for preterm birth per standard deviation fasting glucose 
(0.7mmol/L) was 0.99 (95% CI 0.98-1.00), for early preterm birth 0.99 (0.97-1.02), for large 
for gestational age 1.04 (1.03-1.05) and for severe large for gestational age 1.03 (1.01-1.04).   
Conclusions  Our data suggest that maternal pre-pregnancy impaired fasting glucose 
increases the risk of preterm birth, large for gestational age and severe large for gestational 
age. Data also suggest that the WHO cut-point of impaired fasting glucose is too restrictive 
and lesser levels of fasting glucose also increase the risk of large gestational age and severe 
for severe gestational age in the Chinese population. Further investigation is warranted to 
determine whether and how counselling and interventions for women with pre-pregnancy 
impaired fasting glucose could reduce the risk of preterm birth and large for gestational age. 
Keywords  Cohort Study; Impaired Fasting Glucose; Large for Gestational Age; Large Scale; 















Preterm birth (PTB) is the leading cause of death for children below 5 years of age 
globally.
1
 The estimated global PTB rate was 10.6%, equal to an estimated 14.84 million live 
PTBs in 2014.
2
 PTB complications are estimated to be responsible for 35% of deaths among 
neonates annually, and surviving preterm neonates are at higher risk of respiratory and 
neurodevelopmental complications.
3
 Large for gestational age (LGA), found in 9% to 13% of 
all deliveries, is also associated with multiple risks for both the maternally and the neonates.
4
 
Short term risks of LGA include a two to three fold increase in intrauterine death rate
5
, a 
higher probability of operative delivery and several neonatal morbidities, such as shoulder 
dystocia, obstetric brachial plexus injury and birth fractures and increased risk of trauma to 
the mothers.
6
 There are also long-term risks for neonates, such as obesity, metabolic 
syndrome, and chronic disease in later life.
7,8
 Both PTB and LGA are associated with 
significant costs to health services, and families of PTB and LGA often experience 
considerable psychological and financial hardship.
1,9,10
 These data highlight the critical and 
urgent need to identify risk factors of PTB and LGA.  
The association of diabetic pregnancy with PTB and LGA is well documented.
11-13
 
However, little is known about the impact of maternal pre-pregnancy impaired fasting 
glucose (IFG, typically defined as fasting glucose levels that are above normal but below 
diabetic fasting glucose threshold
14
) on PTB and LGA. From the perspective of health 
management and disease prevention, to identify the impact of pre-pregnancy IFG on PTB and 
LGA are of substantial public health importance since it might be relatively easy to 
implement health interventions, and more helpful to decrease the risk of PTB and LGA for 








In this study, we aimed to investigate the impact of pre-pregnancy IFG on PTB and LGA 
within a large cohort study from Southern China. We also aimed to investigate whether the 
current cut-point of IFG as recommend by the WHO, which was primarily designed to 
identify population who are at greater risk for developing micro- and macrovascular 
complications and diabetes, was appropriate for identifying women at risk of PTB and LGA 
in China. 
 
Material and Methods 
Study participants 
This study was embedded within the framework of the National Free Preconception 
Health Examination Project (NFPHEP), launched by the Chinese National Health and Family 
Planning Commission and the Ministry of Finance in 2010. The NFPHEP has covered all 
rural counties/districts in China since 2013. The project aims to reduce adverse pregnancy 
outcomes through providing free health examination before conception, counselling services 
for reproductive couples who plan to conceive within the next six months and follow up of 
pregnancy outcomes in the households registered as agricultural residents and the migrant 
population who have lived in the local area for more than six months. Project-related design, 
organization, and implementation have been described previously.
17-19
  
We conducted a retrospective cohort study of 728114 women of reproductive age who 
participated in the NFPHEP from 1
st
 January 2013 to 31
st
 December 2017, who successfully 
conceived and then had pregnancy outcomes from 121 counties/districts in 21 cities in 
Guangdong Province, China.  
For the purpose of this study and similar to the previous study,
20 
we developed the 






glucose (FSG) before pregnancy; women with chronic disease (including anaemia, 
hypertension, heart disease, hepatitis B, epilepsy, thyroid disease, chronic nephritis, cancer 
and diabetes); women with newly diagnosed hypertension (systolic blood pressure 
(SBP)≧140mmHg or diastolic blood pressure (DBP)≧90mmHg), and newly diagnosed 
diabetes (FSG≧7.0mmol/L). Women with multiple births or post-term pregnancies (gestation 
age >42 weeks), and with outcomes of miscarriages, induced abortions, birth defects or 
stillbirths were also excluded. 
 The NFPHEP was approved by the Institutional Review Board of the Chinese 
Association of Maternal and Child Health Studies. Written informed consent was obtained 
from the participants before recruitment. The present study was executed jointly by the 
Guangdong Institute of Family Planning Science and Technology and Guangzhou Medical 
University, in which the review boards determined that this study was exempt for ethical 
approval owing to the use of de-identified data. 
Procedures 
Baseline 
The program was based on the primary health and family planning network. All the 
reproductive couples who had planned to conceive and were willing to participate in 
NFPHEP were recruited. Baseline information of participated couples was collected by 
trained local community staff with a structured questionnaire. The questionnaire included 
demographic characteristics (age, educational level, occupation, ethnicity, migration and 
address of residence), history of chronic disease (hypertension, diabetes, heart disease, 
chronic nephritis, anaemia, cancer and psychiatric diseases), history of pregnancy (gravidity 
and parity) and history of adverse pregnancy outcomes (preterm birth, miscarriage, induced 






alcohol consumption and husband smoking). Completeness of the questionnaire was 
reviewed, and data were then entered into the web-based data collection system, which was 
then gathered into the Guangdong Institute of Family Planning Science and Technology. 
Clinical professionals from the local authorized medical institutions then did physical 
examinations and collected blood samples. Body weight, height and blood pressure were 
measured by calibrated instruments and standard specifications. Fasting peripheral venous 
blood samples (not eating anything for at least 8 hours) were collected with the tube 
containing a rapidly effective glycolysis inhibitor, and immediately taken back for 
measurement in accredited laboratories that are affiliated to local authorized medical 
institutions.  
Serum samples were separated and used for analysing FSG concentration within two hours 
of arrival at local laboratories. FSG concentrations were analysed by using an automatic 
biochemistry analyser with the corresponding reagents kits, all of which were certified by the 
China Food and Drug Administration. The Centre of Clinical Laboratories for Quality 
Inspection and Detection of Guangdong Institute of Family Planning Science and Technology 
was responsible for external quality assessment semi-annually and for quality control.
21
 
Interclass correlation coefficients expressing between-person variance as a percentage of the 
total variance, obtained by analysis of replicate pairs of samples drawn at baseline from all 
the counties involved were all higher than 0.98 for FSG concentration. 
Follow up 
After the pre-pregnancy physical examination, all the participated women were followed 
up by trained local community staff by telephone every two months to determine whether 
they had conceived successfully. Local community staff also interviewed the women face to 






period, active smoking, alcohol consumption, and husband smoking during the early stage of 
the pregnancy. Mothers were also interviewed face to face or by telephone within six weeks 
of delivery to collect information on the hospital where they gave birth. Local community 
staff then collected data from the medical records at the reference hospital regarding 
pregnancy outcomes, including current pregnancy outcomes (normal birth, preterm birth, 
miscarriage, induced abortion, stillbirth or birth defects), gestational age (weeks), birth 
weight (grams) and neonatal information (singleton or multiple births). The endpoint of this 
study was to observe the pregnancy outcomes of the participated mothers and the study was 
terminated on 31
st
 December 2017.  
Definition and ascertainment of IFG 
Previous study has suggested that FSG concentration is equal to fasting plasma glucose 
(FPG) concentration,
22
 both of which could be used to screen and diagnose intermediate 
hyperglycaemia or diabetes.
23
 Based on WHO guidelines,
 24
  IFG was defined as FSG 
concentration of 6.1 mmol/L or greater and lower than 7.0 mmol/L, except for those who 
either reported previously diagnosed diabetes or used blood glucose-lowering drugs. 
Information about previously diagnosed diabetes and the use of blood glucose-lowering drugs 
was obtained from the structured questionnaire. After excluding previously diagnosed and 
newly diagnosed diabetes, we then divided the participants into two groups according to their 
pre-pregnancy FSG concentration: women with IFG and women with normoglycemia 
(FSG<6.1mmol/L). 
Outcomes 
The primary outcomes were PTB, early PTB, LGA, and severe LGA. PTB was defined as 






gestational age less than 34 weeks. Gestational age was calculated from the first day of the 
last menstrual period, which was measured by ultrasound at the first trimester of pregnancy. 
Based on the international standards in the INTERGROWTH-21
st
 Project, LGA was defined 
as birth weight by gestational age and gender beyond the 90
th
 percentile, and severe LGA as 






Medians and interquartile range (IRQ) were calculated for age. Frequencies and 
proportions were used to describe the baseline characteristics of the participants and the four 
outcomes among the participants by different baseline characteristics or different categories 
of fasting glucose levels. Chi-square tests were employed to compare the distribution of pre-
pregnancy status of IFG according to different baseline characteristics.  
Log-binomial models based on Generalized Estimating Equations (GEE) were employed 
to estimate the adjusted risk ratios (aRRs) and 95% CIs of PTB and LGA for women with 
pre-pregnancy IFG, and different covariates were adjusted in three models to examine the 
robustness of our findings. We adjusted for sociodemographic characteristics of participants 
in model 1, including age at baseline (19-24 years, 25-29 years, 30-34 years, 35-39 years, or 
40-50 years), ethnicity (Han or others), educational level (primary school or below, junior 
high school, senior high school or college or above), occupation (farmer, worker, servicer or 
others), region (pearl river delta, non-pearl river delta), and migrant population (yes or no). In 
model 2, we additionally adjusted for covariates of history of pregnancy and adverse 
pregnancy outcomes, including first pregnancy (yes or no), primipara (yes or no); history of 
PTB (yes or no), miscarriage (yes or no), induced abortion (yes or no), birth defects (yes or 
no), or stillbirths (yes or no). In model 3, we additionally adjusted for body mass index (BMI, 






women before pregnancy (underweight: <18.5kg/m
2









 smoking status of husband before 
pregnancy and during the early stage of pregnancy (yes or no), smoking and alcohol 
consumption of women before pregnancy and during the early stage of pregnancy (yes or no), 
and passive smoking of women before pregnancy (yes or no).  
We conducted sensitivity analysis with additional adjustment for the length of time from 
pre-pregnancy examination to the last menstrual period (continuous data) or inclusion of 
women with self-reported perceived economic pressure (yes or no). We further used 
subgroup analysis to examine the aRRs and 95% CIs of PTB and LGA for women with the 
pre-pregnancy IFG among different subgroups on the basis of baseline characteristics. 
Among all the subgroup analysis, we adjusted for the most covariates. 
We examined the impact of fasting glucose levels on PTB and LGA by categories, and 
with fasting glucose as a continuous variable (per SD) to determine whether the WHO cut-
point of IFG was appropriate for identifying women at risk of PTB and LGA. We followed 
the analytical protocol used in the Hyperglycaemia and Adverse Pregnancy Outcomes 
(HAPO) study,
27
 fasting glucose was divided in to seven categories with ~50% of all values 
in the two lowest categories and 3% and 1% in the two highest categories, respectively (see 
Table 3 and Figure C.1 footnotes for definition of categories).  
Data were missing in first pregnancy (2729, 0.4%), primipara (2729, 0.4%), body mass 
index (6439, 1.0%), active smoke before pregnancy (4452, 0.7%), passive smoke (4419, 
0.7%), husband smoke before pregnancy (22312, 3.5%), alcohol before pregnancy (6084, 
0.9%), active smoke during early-stage pregnancy (21140, 3.3%), husband smoke during 
early-stage pregnancy (21618, 3.4%), alcohol during early-stage pregnancy (21664, 3.4%). 






other socio-demographic covariates. The significance level was set at 0.05 and all tests were 
two-sided. Statistical analyses were conducted by using Stata (Version 14.0) and Statistic 
software R (version 3.5.2). 
Results 
Participant characteristics 
We excluded 7996 women who did not measure fasting serum glucose (FSG) before 
pregnancy; 31502 women with chronic disease; 7987 women with newly diagnosed 
hypertension; and 2995 women with newly diagnosed diabetes. We also excluded 24073 
women who had miscarriages, induced abortions, birth defects or stillbirths and 13092 
women with multiple births or post-term pregnancies (gestation age≧42 weeks). The 
remaining 640469 participants were included in the final analysis. Figure 1 shows the 
selection of participants for the present study. 44.5% of the women included were from nine 
cities in the Pearl River Delta and 10.2% were migrant populations. The sample size and the 
proportion of the migrant population in each city are shown in Table A.1. The age of the 
participants included in the study ranged from 19 to 50 years, the median age was 26 years 
(IQR 24-29), and 6.2% of the women were older than 35 years. 44.0% of the participants had 
an educational level of junior high school or below, 34.1% and 30.0% had an occupation of 
farmer or worker, 99.3% was Han nationality, and 65.3% were in their first pregnancy. 
Overall, 31006 (4.84%, 95%CI 4.79%-4.89%) women met the criteria of IFG recommend 
by the WHO. Compared with those women with normoglycemia, women with IFG were 
more likely to be living in the non-Pearl River Delta, migrant population, first pregnancy, and 
primipara, overweight and obesity, and had active or passive smoke exposure before 






Impact of pre-pregnancy IFG on PTB, early PTB, LGA, and severe LGA 
The median length of time from pre-pregnancy examination to the last menstrual period 
was 3.1 months (IQR 1.7-5.2). 32640 of 640469 participants had PTB; the PTB rate was 
5.10% (95%CI 5.04%-5.15%) among all the singleton birth. The PTB rate was 5.08% 
(5.02%-5.13%) among women with normoglycemia and 5.45% (5.20%-5.70%) among 
women with pre-pregnancy IFG. 7201 participants had early PTB (1.12%, 1.10%-1.15%), 
which occurred in 6877 (1.13%, 1.10%-1.15%) women with normoglycemia and 324 (1.04%, 
0.93%-1.16%) in women with pre-pregnancy IFG. 
Among 640469 included singleton births, 45532 births were LGA, and the LGA rate was 
7.11% (7.05%-7.17%). 43074 (7.07%, 7.00%-7.13%) LGA births occurred in women with 
normoglycemia, 2458 (7.92%, 7.62%-8.22%) LGA births occurred in women with pre-
pregnancy IFG. 16231 (2.53%, 2.50%-2.57%) births were severe LGA, which occurred in 
15294 (2.51%, 2.47%-2.55%) women with normoglycemia and 937 (3.02%, 2.83%-3.21%) 
women with pre-pregnancy IFG.  
The unadjusted and adjusted RRs are shown in Figure A.1. In the fully adjusted model 
(model 3), compared with women with normoglycemia, women with pre-pregnancy IFG had 
a 7.0% higher risk of PTB, 10.0% higher risk of LGA births and 17.0% higher risk of severe 
LGA births (Table 2). However, no significant association of IFG with early PTB was found. 
In all the three models of PTB, early PTB, LGA, and severe LGA, the aRRs did not 
substantially change. 
Sensitivity and subgroup analyses 
In the sensitivity analyses, the impact of pre-pregnancy IFG on PTB and LGA did not 






examination to last menstrual period (Table B.1) or inclusion of women self-reported with 
perceived economic pressure (Table B.2). 
In the subgroup analyses, the impact of pre-pregnancy IFG on the risk of PTB did not 
appear to be modified by the baseline characteristics (Figure B.1), except that the impact was 
higher among those living in non-Pearl River Delta or residents versus migrants or Han 
ethnicity. The impact of pre-pregnancy IFG on the risk of LGA neither appeared to be 
modified by the baseline characteristics (Figure B.2), except that the impact was greater 
among those living in Pearl River Delta, with multigravida, multipara or with obesity and 
exposure to passive smoking before pregnancy. 
Is WHO cut-point of fasting glucose appropriate for identifying women at risk of PTB and 
LGA 
The unadjusted percentage of women in each group that had each outcome by category of 
fasting glucose is shown in Figure C.1. Generally, the frequencies of four outcomes show an 
increasing trend across the seven categories of fasting glucose except for PTB and early PTB. 
The higher prevalence of LGA and severe LGA is consistent across all fasting glucose 




 category, the risk of LGA and severe LGA showed monotonic 
associations with fasting glucose, while the lowest frequencies of PTB occurred in fasting 
categories 2, 3 and 4. 
Log-binomial models analysis confirmed monotonic associations of fasting glucose with 
the risk of LGA and severe LGA (Table 3). The associations of the four outcomes with 
fasting glucose as a continuous variable suggest stronger associations of fasting glucose 
levels with LGA and severe LGA than that with PTB and early PTB. WHO cut point of IFG 
is too restrictive and lesser levels of fasting glucose also associated with an increased risk of 







This is the first study examined the impact of maternal pre-pregnancy IFG on PTB and 
LGA in a large-scale cohort study, which also investigated whether the WHO cut-point of 
IFG is appropriate for identifying women at risk of PTB and LGA. In this study, we found 
that pre-pregnancy IFG increases the risk of PTB, LGA, and severe LGA by 7.0%, 10.0%, 
and 17.0%, respectively, and the impact is consistent for the various subgroups of women 
with various baseline characteristics. We also found that WHO cut-point for IFG is too 
restrictive and lesser levels of fasting glucose also increase the risk of LGA and severe LGA. 
In relation to other study 
Although there were inconsistent results in terms of the associations of pregnancy 
hyperglycaemia/diabetes with some adverse pregnancy outcomes (such as PTB) in previous 
studies,
28,29 
 it is now well accepted that reducing blood glucose in pregnancy reduces the 
adverse pregnancy and postpartum complications. It was unexpected that there were very few 
studies have investigated the impact of pre-pregnancy hyperglycaemia on adverse pregnancy 
outcomes. To our knowledge, only two studies among the few studies pertaining to pre-
pregnancy IFG and adverse pregnancy outcomes.
30,31 
Salman and colleagues analysed 
singleton pregnancies of 1945 women in Israel, but they only found the association of pre-
pregnancy IFG with abnormal glucose challenge test (GCT) and gestational diabetes mellitus 
(GDM), rather than with increased risk of PTB and LGA.
30
 Hu and colleagues conducted a 
prospective study of 16,890 women in central China to estimate the incidence of PTB and 
identify maternal risk factors before pregnancy from 2010 to 2013.
31
 Although they found 
that women with pre-pregnancy hyperglycaemia (FBG level >6.1mmol/L) had an increased 






6.1mmol/L or less) after adjustment (6.3% vs. 3.6%, aOR 1.69, 1.09-2.62), the definition of 
hyperglycaemia in this study was unclear, which reduced the strength of the study.
31
  
The discrepancies of the associations of IFG or hyperglycaemia both before and during 
pregnancy with the risk of PTB and LGA might be related to the measurement of blood 
glucose and the threshold for hyperglycaemia. Evidence from the recent meta-analyses 
showed that there was a positive linear association with LGA for all glucose exposures across 
the distribution of glucose concentrations during pregnancy, and no clear evidence of a 
threshold. However, fasting glucose concentration was inversely association with PTB (aOR 
0.77, 95%CI 0.62-0.96), whereas the association between post-load concentration and PTB 
was more inconsistent: weakly positive for 50g 1-hour oral glucose challenge test (OGCT) or 
75g 2-hour oral glucose tolerance test (OGTT), and inverse with 100g 2-hour OGTT.
13 
In our 
study, we also found linear associations of fasting glucose with LGA and severe LGA but not 
PTB, suggesting a possible threshold of pre-pregnancy fasting glucose for identifying women 
who had increased risk of LGA. Of noting, although there was no linear association of fasting 
glucose with PTB, we found inverse associations in fasting glucose categories 2, 3 and 4, 
which suggested categories 1, 5, 6, and 7 are associated with an increased risk of PTB if we 
take categories 2, 3 and 4 as the reference.  
Explanations of pre-pregnancy IFG associated with increased risk of PTB and LGA 
The causes of PTB and LGA are complex and multifactorial. However, the impact of pre-
pregnancy IFG on PTB and LGA could be explained by the following aspects. First, IFG is 
associated with impaired insulin secretion and impaired suppression of hepatic glucose 
output, and is associated with progressively greater risk of developing micro- and 
macrovascular complications and then associated with an increased risk of diabetes, which 
are the identified risk factors of PTB and LGA.
32 






hyperglycaemia is associated with an increased risk of GDM, which might increase the risk 
of placental inflammation, a known pathogenesis of LGA and a known contributor to PTB.
33
 
Other conditions developed from pre-pregnancy IFG or hyperglycemia might also lead to 
PTB and LGA, such as pre-eclampsia and hypertensive associated conditions (such as 
intrauterine growth restriction and placental abruption).
34
 Additionally, the persistent IFG or 
hyperglycaemia in the placenta transports to the fetus that stimulates islet β-cell proliferation 
and leads to further hyperinsulinemia, which is also a known contributor to LGA.
35 
Third, 
previous studies reported that women with IFG or hyperglycemia had higher levels of 
insulin-like growth factor I (IGF-I), which has the function of promoting placental nutrient 
transfer to enhance fetal growth.
36
 Overall, these possible explanations of pre-pregnancy IFG 
or hyperglycemia associated with increased risk of PTB and LGA might be similar to that of 
diabetes and GDM or gestational hyperglycemia, because pre-pregnancy blood glucose level 
and glucose tolerance are the basis of blood glucose level and glucose tolerance during 
pregnancy, which usually elevates during the pregnancy. Further studies on the potential 
mechanisms of IFG or hyperglycemia related to PTB and LGA are therefore needed.     
Strengths and weakness of this study 
The major strength of this study is the sample size. For this cohort, we recruited 640469 
participants and followed up pregnancy outcomes with strict quality controls. The number of 
IFG or fasting glucose categories and events per baseline variables or each fasting glucose 
categories were enough that the multivariable regression models were not over-fitted.
20
 The 
large sample size allowed us to verify the robust associations of pre-pregnancy IFG with 
increased risk of PTB and LGA among different subgroups on the basis of baseline 






WHO cut-point of IFG is appropriate for identifying women who are at risk of PTB and 
LGA.  
The study has some limitations. First, a 2-hour glucose level was not measured in the 
NFPHEP project. Women who met the criteria for diabetes might be included and 
misclassified to the IGF group, which could lead to the overestimation of associations of IFG 
with PTB and LGA. However, the prevalence of IFG estimated was similar to a previous 
study among Chinese women of reproductive age.
15
 Second, some important information on 
pregnancy complications and obstetrics were missing too much or not collected in the 
NFPHEP. For example, data on gestational hypertension and diabetes were missing in 99.1% 
of participants, and data on gestational weight gain and causes of PTB (spontaneous versus 
indicated) were not collected, both of which make the interpretation of our results difficult. 
Thus, further studies are warranted to fully understand the impact of pre-pregnancy IFG on 
IFG and LGA. Furthermore, we were not able to explore the effects of family income on PTB 
and LGA as such information also was lacking for the vast majority of women. However, the 
aRRs did not change substantially after additionally adjusting for economic pressure, which 
is correlated with family income.
37 
Third, we may have underestimated the associations of 
IFG with LGA because lower prevalence rate of LGA in our study, which may not only due 
to the use of the INTERGROWTH-21
st
 standards, but also due to some policy interventions 
implemented in China, such as maternal system health care policy that has covered more than 
95% pregnant and monitored several risk factors for adverse outcomes during the 
pregnancy.
38  Finally, although this is a large scale cohort study, the socio-demographic 
characteristics, economic, culture, nutritional models and medical service level could not be 
representative of other countries and regions, suggesting that results from the present study 







Our findings have important clinical and public health implications. Both PTB and LGA 
drive the need for neonatal and obstetric care and are related to neonatal and maternal 
mortality and morbidity. Whilst there is a health burden, clinicians and health professionals 
pay less attention to IFG screening and interventions due to lack of conclusive evidence on 
associations of pre-pregnancy IFG with PTB and LGA. Our findings from 640,469 women 
confirmed a statistically significant increase in risk estimate by 7.0% of PTB, 10.0% of LGA 
and 17.0% of severe LGA in those women with pre-pregnancy IFG defined by the WHO cut-
point compared with those women with normoglycaemia. This suggested that screening for 
IFG before pregnancy and taking interventions, such as diet, weight control and physical 
exercise to control fasting glucose before pregnancy,
15,16
 might be necessary for reducing the 
risk of PTB, LGA, and severe LGA. The finding also suggested that WHO cut-point for IFG 
is restrictive and lesser levels of pre-pregnancy fasting glucose also increase the risk of LGA 
and severe LGA. Overall, to prevent the risk of PTB, LGA and severe LGA, clinicians and 
health providers should carry out continuous management of blood glucose both before and 
during pregnancy. 
Conclusion 
In conclusion, for the first time, in this large retrospective cohort study, pre-pregnancy 
IFG defined by the WHO cut-point increases the risk of PTB, LGA, and severe LGA, and the 
WHO cut-point for IFG is restrictive and lesser levels of fasting glucose also increase risk of 
LGA and severe LGA. The NFPHEP potentially offers a unique platform to identify women 
with pre-pregnancy IFG. However, the WHO cut-point of IFG is not appropriate for 






determine whether and how counselling and interventions for women with IFG before 
pregnancy can reduce the risk of PTB and LGA.  
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Table 1. Maternal baseline characteristics with respect to pre-pregnancy status of FSG 













Region     
Pearl river delta 272992(44.8%) 11916(38.4%) 284908(44.5%) 14986(45.9%) 3449(47.9%) 21333(46.9%) 7563(46.6%) 
Non-Pearl River delta 336471(55.2%) 19090(61.6%) 355561(55.5%) 17654(54.1%) 3752(52.1%) 24199(53.2%) 8668(53.4%) 
Migrant population     
Yes 617622(10.1%) 3532(11.4%) 65154(10.2%) 3204(9.8%) 728(10.1%) 5767(12.7%) 2067(12.7%) 
No 547841(89.9%) 27474(88.6%) 575315(89.8%) 29436(90.2%) 6473(89.9%) 39765(87.3%) 14164(87.3%) 
Age at baseline (years)     
19~24 209143(34.3%) 10055(32.4%) 219198(34.2%) 11125(34.1%) 2504(34.8%) 13613(29.9%) 5006(30.8%) 
25~29 273151(44.8%) 13824(44.6%) 286975(44.8%) 13982(42.8%) 3029(42.1%) 19710(43.3%) 7048(43.4%) 
30~34 90314(14.8%) 4894(15.8%) 95298(14.9%) 5080(15.6%) 1139(15.8%) 8139(17.9%) 2879(17.7%) 
35~39 31776(5.2%) 1863(6.0%) 33639(5.3%) 2063(6.3%) 433(6.0%) 3439(7.6%) 1094(6.7%) 
40~50 5079(0.8%) 370(1.2%) 5449(0.9%) 390(1.2%) 96(1.1%) 631(1.4%) 204(1.3%) 
Education     
Primary school or below 13558(2.2%) 809(2.6%) 14367(2.2%) 738(2.3%) 161(2.2%) 879(1.9%) 305(2.5%) 
Junior high school 254231(41.7%) 13542(43.7%) 267773(41.8%) 14560(44.6%) 3270(45.4%) 18778(41.2%) 7021(43.3%) 
Senior high school 161776(26.5%) 7815(25.2%) 169591(26.5%) 8234(25.2%) 1773(24.6%) 11584(25.4%) 4071(25.1%) 
College or above 179898(29.5%) 8840(28.5%) 18738(29.5%) 9108(27.9%) 1997(27.7%) 14291(31.4%) 4834(29.8%) 
Occupation     






Worker 182967(30.0%) 9243(29.8%) 192210(30.0%) 9989(30.6%) 2263(31.4%) 13153(28.9%) 4647(28.6%) 
Servicer 83207(13.7%) 4049(13.1%) 87256(13.6%) 3857(11.8%) 824(11.4%) 5856(12.9%) 2064(12.7%) 
Others 136114(22.3%) 6660(21.5%) 142774(22.3%) 7003(21.5%) 1528(21.2%) 11329(24.9%) 3928(24.2%) 
Ethnicity     
Han 605440(99.3%) 30776(99.3%) 636216(99.3%) 32408(99.3%) 7139(99.1%) 45159(99.2%) 16105(99.2%) 
Other 4023(0.7%) 230(0.7%) 4253(0.7%) 232(0.7%) 62(0.9%) 373(0.8%) 126(0.8%) 
History of pregnancy and adverse pregnancy outcomes     
History of preterm 1818(0.3%) 66(0.2%) 1884(0.3%) 241(0.7%) 67(0.9%) 178(0.4%) 53(0.3%) 
History of miscarriage 17258(2.8%) 748(2.4%) 18006(2.8%) 982(3.0%) 247(3.4%) 1491(3.3%) 492(3.0%) 
History of induced abortion 75836(12.4%) 3507(11.3%) 79343(12.4%) 4059(12.4%) 905(12.6%) 6665(14.6%) 2284(14.1%) 
History of birth defect 1638(0.3%) 40(0.1%) 1678(0.3%) 86(0.3%) 29(0.4%) 159(0.4%) 53(0.3%) 
History of stillbirth 5019(0.8%) 209(0.7%) 5228(0.8%) 314(1.0%) 73(1.0%) 485(1.1%) 158(1.0%) 
First pregnancy♯ 395168(64.8%) 21038(67.9%) 416206(65.0%) 21516(65.9%) 4742(65.8%) 27287(60.0%) 10055(65.1%) 
Primipara♯ 44192(72.4%) 23292(75.1%) 464784(72.6%) 23963(73.4%) 5280(73.3%) 30819(67.7%) 11279(69.5%) 
Pre-pregnancy physical examination     
Body mass index (kg/m2) ♯     
Underweight (<18.5) 124288(20.4%) 5515(17.8%) 129803(20.3%) 6876(21.1%) 1536(21.3%) 7496(16.5%) 2698(16.6%) 
Normal (18.5-24.0) 405190(66.5%) 19824(63.9%) 425014(66.4%) 21319(65.3%) 4697(65.2%) 30406(66.8%) 10707(66.0%) 
Overweight (24.0-28.0) 61389(10.1%) 4329(14.0%) 65718(10.3%) 3348(10.3%) 714(9.9%) 5672(12.5%) 2004(12.4%) 
Obesity(≥28) 12395(2.0%) 1100(3.6%) 13495(2.1%) 751(2.3%) 176(2.4%) 1327(3.91%) 527(3.3%) 
Lifestyle before pregnancy   
Active smoke♯ 1471(0.2%) 79(0.3%) 1550(0.2%) 94(0.3%) 17(0.2%) 148(0.3%) 40(0.3%) 






Husband smoke♯ 164999(27.1%) 8947(28.9%) 173946(27.2%) 9270(28.4%) 2089(29.0%) 12462(27.4%) 4498(27.7%) 
Alcohol♯ 37912(6.2%) 1765(5.7%) 39677(6.2%) 2172(6.7%) 501(7.0%) 3281(7.2%) 1155(7.1%) 
Lifestyle during early pregnancy   
Active smoke♯ 3824(0.6%) 245(0.8%) 4069 (0.6%) 214(0.7%) 38(0.5%) 336(0.7%) 132(0.8%) 
Husband smoke♯ 124865(20.5%) 6270(20.2%) 131135(20.5%) 6453(19.8%) 1450(20.1%) 8862(19.5%) 3311(20.4%) 
Alcohol# 7226(1.2%) 401(1.3%) 7627(1.2%) 372(1.1%) 76(1.1%) 592(1.3%) 206(1.3%) 
FSG: Fasting serum Glucose. IFG: impaired fasting glucose. PTB: preterm birth. LGA: large for gestational age.  
♯ Denominators provided as missing data existed. 




Table 2. aRRs for PTB, LGA and severe LGA according to maternal pre-pregnancy IFG 
 Events Model 1♯  Model 2┼  Model 3╪ 
  IRR(95%CI) P  IRR(95%CI) P  IRR(95%CI) P 
Preterm birth          
Normoglycaemia 30950(5.1%) 1.00(reference) …  1.00(reference) …  1.00(reference) … 
IFG 1690(5.5%) 1.07(1.02-1.12) 0.004  1.07(1.02-1.12) 0.008  1.07(1.02-1.12) 0.010 
Early pretwem birth         
Normoglycaemia  6877 (1.1%) 1.00(reference) …  1.00(reference) …  1.00(reference) … 
IFG 324(1.0%) 0.93(0.83-1.04) 0.202  0.93(0.83-1.03) 0.175  0.92(0.83-1.03) 0.159 
Large for gestational age        
Normoglycemia 43074(7.1%) 1.00(reference) …  1.00(reference) …  1.00(reference) ... 






Severe large for gestational age        
Normoglycaemia 15294(2.5%) 1.00(reference) …  1.00(reference) …  1.00(reference) … 
IFG 937(3.0%) 1.20(1.12-1.27) <0.001  1.20(1.12-1.27) <0.001  1.17(1.10-1.26) <0.001 
aRRs=adjusted risk ratios; PTB=preterm birth; LGA=large for gestational age, IFG=impaired fasting glucose.  
♯ Model 1: risk ratios were adjusted for sociodemographic characteristics of maternal (age, education level, occupation, ethnicity, region and 
migrant population).  
┼ Model 2: risk ratios were additionally adjusted for history of pregnancy (first gestation and primipara) and history of adverse pregnancy 
outcomes (preterm birth, miscarriage, induced abortion, birth defect, and stillbirth). 
╪ Model 3: risk ratios were adjusted for pre-pregnancy body mass index, active smoking, passive smoking, husband smoking and alcohol 
consumption status of maternal before pregnancy and active smoking, husband smoking, alcohol drinking status during early stage of 
pregnancy, in additional to the covariates in Model 2. 
 
Table 3. aRRs for impact of pre-pregnancy fasting glucose on PTB, LGA and severe LGA 
Glucose 
categories 
Total N (N with 
outcome) 
Model 1♯  Model 2┼ Model 3╪ 
IRR(95%CI) P  IRR(95%CI) P  IRR(95%CI) P 
PTB         
1 165897(8782) 1.00(reference) …  1.00(reference) …  1.00(reference) … 
2 144431(7164) 0.94(0.91-0.97) <0.001  0.94(0.92-0.97) <0.001  0.94(0.91-0.97) <0.001 
3 174513(8598) 0.93(0.90-0.96) <0.001  0.93(0.91-0.96) <0.001  0.93(0.90-0.96) <0.001 
4 93354(4748) 0.96(0.93-0.99) 0.015  0.96(0.93-0.99) 0.026  0.96(0.93-0.99) 0.022 
5 36122(1936) 1.01(0.96-1.06) 0.788  1.00(0.96-1.05) 0.855  1.00(0.96-1.05) 0.904 
6 19198(1032) 1.02(0.95-1.08) 0.634  1.01(0.95-1.08) 0.684  1.01(0.95-1.08) 0.736 
7 6954(380) 1.03(0.93-1.14) 0.578  1.02(0.93-1.15) 0.635  1.02(0.92-1.12) 0.689 
Per 1 SD 640469(32640) 0.99(0.98-1.00) 0.179  0.99(0.98-1.00) 0.177  0.99(0.98-1.00) 0.139 
Early PTB          






2 144431(1565) 0.95(0.89-1.02) 0.107  0.95(0.89-1.02) 0.129  0.95(0.89-1.01) 0.119 
3 174513(1942) 0.97(0.91-1.04) 0.343  0.97(0.91-1.04) 0.394  0.97(0.91-1.04) 0.372 
4 93354(1089) 1.02(0.94-1.09) 0.671  1.02(0.95-1.10) 0.631  1.02(0.94-1.09) 0.673 
5 36122(442) 1.06(0.96-1.18) 0.244  1.06(0.96-1.18) 0.263  1.06(0.95-1.17) 0.282 
6 19198(195) 0.89(0.77-1.03) 0.128  0.89(0.77-1.03) 0.120  0.89(0.77-1.03) 0.109 
7 6954(67) 0.84(0.66-1.07) 0.166  0.84(0.66-1.07) 0.159  0.84(0.66-1.07) 0.147 
Per 1 SD 640469(7201) 0.99(0.97-1.02) 0.638  0.99(0.97-1.02) 0.633  0.99(0.97-1.02) 0.583 
LGA         
1 165897(10795) 1.00(reference) …  1.00(reference) …  1.00(reference) ... 
2 144431(9860) 1.03(1.00-1.05) 0.043  1.02(1.00-1.05) 0.087  1.02(0.98-1.05) 0.154 
3 174513(12616) 1.07(1.04-1.10) <0.001  1.06(1.04-1.09) <0.001  1.06(1.03-1.08) <0.001 
4 93354(7285) 1.14(1.11-1.17) <0.001  1.14(1.10-1.17) <0.001  1.12(1.09-1.16) <0.001 
5 36122(2922) 1.19(1.14-1.24) <0.001  1.19(1.14-1.24) <0.001  1.17(1.13-1.22) <0.001 
6 19198(1504) 1.16(1.10-1.22) <0.001  1.16(1.10-1.23) <0.001  1.14(1.08-1.20) <0.001 
7 6954(550) 1.18(1.08-1.27) <0.001  1.18(1.09-1.28) <0.001  1.15(1.06-1.25) <0.001 
Per 1 SD 640469(45532) 1.05(1.04-1.06) <0.001  1.05(1.04-1.06) <0.001  1.04(1.03-1.05) 0.001 
Severe LGA        
1 165897(4018) 1.00(reference) …  1.00(reference) …  1.00(reference) … 
2 144431(3438) 0.97(0.93-1.01) 0.172  0.97(0.92-1.01) 0.149  0.96(0.92-1.01) 0.114 
3 174513(4482) 1.03(0.99-1.08) 0.151  1.03(0.99-1.07) 0.193  1.02(0.98-1.07) 0.327 
4 93354(2472) 1.05(1.00-1.11) 0.039  1.05(1.00-1.11) 0.040  1.04(0.99-1.10) 0.121 
5 36122(1057) 1.17(1.10-1.25) <0.001  1.17(1.10-1.25) <0.001  1.15(1.08-1.23) <0.001 






7 6954(204) 1.18(1.03-1.35) 0.029  1.18(1.03-1.36) 0.026  1.15(1.01-1.32) 0.024 
Per 1 SD 640469(16231) 1.03(1.02-1.05) <0.001  1.03(1.02-1.05) <0.001  1.03(1.01-1.04) <0.001 
aRRs= adjusted risk ratios; PTB=preterm birth; LGA=large for gestational age.  
Fasting glucose categories are defined as follows: category 1: less than 4.3mmol/L; category 2: 4.3-4.7mmol/L; category 3: 4.7-5.2mmol/L; 
category 4: 5.2-5.6mmol/L; category 5: 5.6-6.2mmol/L; category 6: 6.2-6.7mmol/L; category 7: 6.7-7.0mmol/L.  
♯ Model 1: risk ratios were adjusted for sociodemographic characteristics of maternal (age, education level, occupation, ethnicity,  
 ┼ Model 2: risk ratios were additionally adjusted for history of pregnancy (first gestation and primipara) and history of adverse pregnancy 
outcomes (preterm birth, miscarriage, induced abortion, birth defect, and stillbirth).  
╪ Model 3: risk ratios were adjusted for pre-pregnancy body mass index, active smoking, passive smoking, husband smoking and alcohol 
consumption status of maternal before pregnancy and active smoking, husband smoking, alcohol drinking status during early stage of 
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728114 women had pregnancy outcomes in NFPHEP from 121 counties in 21 cities in 
Guangdong Province from 1st Jan 2013 to 31st Dec 2017 
7996 women who did not have fasting serum glucose test before 
pregnancy were excluded 
720118 women with fasting serum glucose test had pregnancy outcomes 
79649 women were excluded: 
31502 women with chronic diseases; 
7987 women with systolic blood pressure ≥ 140 mmHg, or 
diastolic blood pressure ≥ 90mmHg; 
2995 women with fasting serum glucose ≥ 7.0 mmol/L; 
24073 women with abortion (spontaneous or induced) or 
stillbirth; 
13092 women with post-term (gestational week ≥42 weeks) or 
multiple births.  
640469 women who had singleton livebirths were included in the cohort study 
